CSIMarket Company Name, Ticker, Competitors, else..


Interpace Biosciences Inc   (PDII)
Other Ticker:  
 

Interpace Biosciences Inc

PDII's Fundamental analysis



Looking into Interpace Biosciences Inc growth rates, revenue grew by 6.19 % in III. Quarter 2024 from the same quarter a year ago.

Medical Equipment & Supplies industry recorded growth of revenues by 1.71 %

Interpace Biosciences Inc 's net income grew by 631.43 % in III. Quarter 2024 year on year, above company average,

• More on PDII's Growth


Interpace Biosciences Inc
current PE on trailing twelve month basis is below Medical Equipment & Supplies industry average.

Interpace Biosciences Inc PEG ratio is at -0 Interpace Biosciences Inc realized cash reduction of $ -0.37 per share in trailing twelve-month period.
Company
0
PE TTM   
Industry
346.16
PE TTM    
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.53.


• More on PDII's Valuation
 
 Total Debt (Millions $) 6
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 105,450
 Net Income/Employee (TTM) $ 9,045
 Receivable Turnover (TTM) 7.24
 Tangible Book Value (Per Share $) -13.04

Interpace Biosciences Inc
current PE on trailing twelve month basis is below Medical Equipment & Supplies industry average.

Interpace Biosciences Inc PEG ratio is at -0 Interpace Biosciences Inc realized cash outflow of $ -0.37per share in trailing twelve-month period.
Company
0
PE TTM   
Industry
346.16
PE TTM    
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.53.


• More on PDII's Valuation

•  Market Capitalization (Millions $) -
•  Shares Outstanding (Millions) 4
•  Employees 400
•  Revenues (TTM) (Millions $) 42
•  Net Income (TTM) (Millions $) 4
•  Cash Flow (TTM) (Millions $) -2
•  Capital Exp. (TTM) (Millions $) -1
•  Total Debt (Millions $) 6
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 105,450
•  Net Income/Employee(TTM) $ 9,045
•  Receivable Turnover Ratio (TTM) 7.24
•  Tangible Book Value (Per Share $) -13.04

•  Market Capitalization (Millions $) -
•  Shares Outstanding (Millions) 4
•  Employees 400
•  Revenues (TTM) (Millions $) 42
•  Net Income (TTM) (Millions $) 4
•  Cash Flow (TTM) (Millions $) -2
•  Capital Exp. (TTM) (Millions $) -1


    PDII's Profitability Comparisons
Interpace Biosciences Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in III. Quarter 2024 to 16.56 % from 19.74 % in II. Quarter.

Interpace Biosciences Inc net profit margin of 11.12 % is currently ranking no. 31 in Medical Equipment & Supplies industry, ranking no. 105 in Healthcare sector and number 1211 in S&P 500.


Profitability by Segment
Total 11.12 %



  Ratio
•   Capital Ratio (MRQ) 0.59
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 3.14
•  Inventory Turnover Ratio (TTM) -



Interpace Biosciences Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in III. Quarter 2024 to 16.56 % from 19.74 % in II. Quarter.

Interpace Biosciences Inc net profit margin of 11.12 % is currently ranking no. 31 in Medical Equipment & Supplies industry, ranking no. 105 in Healthcare sector and number 1211 in S&P 500.

• More on PDII's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com